Press communication
Lund, Sweden, December 19 2023
This is a translation of the Swedish press release published 2023-12-19
Market preparations for the launch in the U.S. continue with the newly established subsidiary, Neola Medical, Inc., in the U.S, new patent for the company’s disposables in Europe, and a directed share issue of 20 MSEK that can secure funding for 2024, focusing on the company’s clinical studies in the U.S. Neola Medical’s CEO provides more details in the winter investor letter of 2023.
In the winter investor letter, CEO Hanna Sjöström shares more about receiving The Arvind Hundal Scaleup Award at the NOME Annual Meeting and Startup Competition 2023 in Copenhagen, the patent approval for the company’s disposables, and the potential financing through a directed share issue of 20 MSEK in 2024. Furthermore, she provides insights into the ongoing preparatory work for the launch of Neola® in the U.S., gaining momentum through the newly established subsidiary, Neola Medical, Inc.
Read the investor letter here: Neola Medical Investor Letter Winter 2023
Read the press release, including the investor letter, here (in Swedish): PM Neola Medical Investerarbrev vinter 2023
For further information, contact:
Hanna Sjöström, CEO Neola Medical, phone: +46 (0)760-10 71 16, e-mail: hanna.sjostrom@neolamedical.com
Neola Medical AB (publ) develops medical technology device for continuous monitoring of preterm born infants’ lungs. Immediate detection of complications provides the possibility of early treatment and improved health care. The patented technology is based on a spectroscopic method developed at Lund University in Sweden. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB.